Nature Communications (Oct 2021)
Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy
- Hussein A. Abbas,
- Dapeng Hao,
- Katarzyna Tomczak,
- Praveen Barrodia,
- Jin Seon Im,
- Patrick K. Reville,
- Zoe Alaniz,
- Wei Wang,
- Ruiping Wang,
- Feng Wang,
- Gheath Al-Atrash,
- Koichi Takahashi,
- Jing Ning,
- Maomao Ding,
- Hannah C. Beird,
- Jairo T. Mathews,
- Latasha Little,
- Jianhua Zhang,
- Sreyashi Basu,
- Marina Konopleva,
- Mario L. Marques-Piubelli,
- Luisa M. Solis,
- Edwin Roger Parra,
- Wei Lu,
- Auriole Tamegnon,
- Guillermo Garcia-Manero,
- Michael R. Green,
- Padmanee Sharma,
- James P. Allison,
- Steven M. Kornblau,
- Kunal Rai,
- Linghua Wang,
- Naval Daver,
- Andrew Futreal
Affiliations
- Hussein A. Abbas
- Division of Cancer Medicine, Medical Oncology Fellowship, University of Texas M D Anderson Cancer Center
- Dapeng Hao
- Division of Cancer Medicine, Medical Oncology Fellowship, University of Texas M D Anderson Cancer Center
- Katarzyna Tomczak
- Department of Genomic Medicine, University of Texas M D Anderson Cancer Center
- Praveen Barrodia
- Department of Genomic Medicine, University of Texas M D Anderson Cancer Center
- Jin Seon Im
- Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center
- Patrick K. Reville
- Division of Cancer Medicine, Medical Oncology Fellowship, University of Texas M D Anderson Cancer Center
- Zoe Alaniz
- Department of Leukemia, University of Texas MD Anderson Cancer Center
- Wei Wang
- Department of Hematopathology, University of Texas MD Anderson Cancer Center
- Ruiping Wang
- Department of Genomic Medicine, University of Texas M D Anderson Cancer Center
- Feng Wang
- Department of Genomic Medicine, University of Texas M D Anderson Cancer Center
- Gheath Al-Atrash
- Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center
- Koichi Takahashi
- Department of Leukemia, University of Texas MD Anderson Cancer Center
- Jing Ning
- Department of Biostatistics, University of Texas MD Anderson Cancer Center
- Maomao Ding
- Department of Biostatistics, University of Texas MD Anderson Cancer Center
- Hannah C. Beird
- Department of Genomic Medicine, University of Texas M D Anderson Cancer Center
- Jairo T. Mathews
- Department of Leukemia, University of Texas MD Anderson Cancer Center
- Latasha Little
- Department of Genomic Medicine, University of Texas M D Anderson Cancer Center
- Jianhua Zhang
- Department of Genomic Medicine, University of Texas M D Anderson Cancer Center
- Sreyashi Basu
- Department of Immunology, University of Texas MD Anderson Cancer Center
- Marina Konopleva
- Department of Leukemia, University of Texas MD Anderson Cancer Center
- Mario L. Marques-Piubelli
- Department Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
- Luisa M. Solis
- Department Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
- Edwin Roger Parra
- Department Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
- Wei Lu
- Department Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
- Auriole Tamegnon
- Department Translational Molecular Pathology, University of Texas MD Anderson Cancer Center
- Guillermo Garcia-Manero
- Department of Leukemia, University of Texas MD Anderson Cancer Center
- Michael R. Green
- Department of Genomic Medicine, University of Texas M D Anderson Cancer Center
- Padmanee Sharma
- Department of Immunology, University of Texas MD Anderson Cancer Center
- James P. Allison
- Department of Immunology, University of Texas MD Anderson Cancer Center
- Steven M. Kornblau
- Department of Leukemia, University of Texas MD Anderson Cancer Center
- Kunal Rai
- Department of Genomic Medicine, University of Texas M D Anderson Cancer Center
- Linghua Wang
- Department of Genomic Medicine, University of Texas M D Anderson Cancer Center
- Naval Daver
- Department of Leukemia, University of Texas MD Anderson Cancer Center
- Andrew Futreal
- Department of Genomic Medicine, University of Texas M D Anderson Cancer Center
- DOI
- https://doi.org/10.1038/s41467-021-26282-z
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 13
Abstract
The response rate of relapsed/refractory acute myeloid leukemia patients to PD-1 checkpoint blockade is low and unpredictable. Authors here show by single cell RNA sequencing, T cell receptor profiling and genomic analysis that the phenotypes and repertoire of CD8 + T cells and loss of chromosome 7/7q are important determinants of response.